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TSG-6 (TNF--stimulated gene/protein 6), a hyaluronan
(HA)-binding protein, has been implicated in the negative reg-
ulation of inflammatory tissue destruction. However, little is
known about the tissue/cell-specific expression of TSG-6 in
inflammatory processes, due to the lack of appropriate
reagents for the detection of this protein in vivo. Here, we
report on the development of a highly sensitive detection sys-
tem and its use in cartilage proteoglycan (aggrecan)-induced
arthritis, an autoimmune murine model of rheumatoid
arthritis. We found significant correlation between serum
concentrations of TSG-6 and arthritis severity throughout
the disease process, making TSG-6 a better biomarker of
inflammation than any of the other arthritis-related cyto-
kines measured in this study. TSG-6 was present in arthritic
joint tissue extracts together with the heavy chains of inter-
-inhibitor (II). Whereas TSG-6 was broadly detectable in
arthritic synovial tissue, the highest level of TSG-6 was co-lo-
calized with tryptases in the heparin-containing secretory
granules of mast cells. In vitro, TSG-6 formed complexes with
the tryptases murine mast cell protease-6 and -7 via either
heparin or HA. In vivo TSG-6-tryptase association could also
be detected in arthritic joint extracts by co-immunoprecipita-
tion. TSG-6 has been reported to suppress inflammatory tissue
destruction by enhancing the serine protease-inhibitory activity
of II against plasmin. TSG-6 achieves this by transferring
heavy chains from II to HA, thus liberating the active bikunin
subunit of II. Because bikunin is also present inmast cell gran-
ules, we propose that TSG-6 can promote inhibition of tryptase
activity via a mechanism similar to inhibition of plasmin.
TSG-6 (the product of tumor necrosis factor -stimulated
gene-6; also called Tnfaip6 or Tnfip6) is a hyaluronan (HA)3-
binding protein, secreted by a variety of cells in response to
proinflammatory stimuli (1). TSG-6 protein has been detected
in large quantities in the synovial fluids and synovial tissues of
inflamed joints of patients with rheumatoid arthritis (2–4).
Recombinant mouse TSG-6 (rmTSG-6) has demonstrated
anti-inflammatory and chondroprotective effects in mouse
models of rheumatoid arthritis (5). TSG-6 forms a stable com-
plex with a heavy chain (HC) of inter--trypsin inhibitor (II),
a major serine protease inhibitor in serum (3). Because II
exhibits increased inhibitory activity against plasmin, a key acti-
vator ofmatrixmetalloproteinases after encounteringTSG-6, it
has been postulated that TSG-6 exerts its anti-inflammatory
and chondroprotective effects primarily through inhibition of
the protease network (6, 7).
TSG-6 consists of a “Link” module and a “CUB” (comple-
ment C1s/C1r-, uEGF-, BMP-1-like) domain. The positively
charged Link module binds various glycosaminoglycans
(GAGs), including HA, chondroitin sulfate, heparin, and hepa-
ran sulfate (1, 8–10). The CUB domain of TSG-6 is similar to
the CUB module found in several developmentally regulated
proteins (11) that are thought to be involved in protein-pro-
tein interactions (12–14). However, to date, only fibronectin
has been shown to bind to the CUB domain of TSG-6 (15).
TSG-6 is not expressed constitutively but can be induced by
proinflammatory cytokines or LPS (2, 16, 17). In contrast, anti-
inflammatory cytokines, such as IL-4 or IL-10, suppress TSG-6
expression either directly or via inhibition of LPS/Toll-like
receptor-induced cell activation (17).
TSG-6 canmodulate the binding ofHA to the cell surfaceHA
receptor, CD44 (18). Treatment of leukocytes with soluble
HATSG-6 complex has been shown to inhibit the CD44-me-
diated adhesion of these cells to immobilized HA in vitro (19).
Because the CD44-supported adhesion (rolling) of leukocytes
on HA-covered surfaces of inflamed vascular endothelium is
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required for the emigration of these cells from the bloodstream
into inflamed tissue (20), inhibition of this adhesion step by the
HATSG-6 complex could have a negative impact on the
extravasation of inflammatory cells. The in vitro observations
are consistent with in vivo studies reporting reduced leukocyte
influx into the arthritic joints of TSG-6-treated mice (5, 6) and
enhanced leukocyte extravasation in the joints of TSG-6-defi-
cient mice (21). Collectively, the in vivo observations lend sup-
port to the concept that TSG-6 has a critical role in the resolu-
tion of inflammation, but this function of TSG-6 may rely on
more than one mechanism.
One of the initial goals of the present study was to develop a
sensitive detectionmethod formeasuring the concentrations of
TSG-6 in serum and synovial fluid samples of mice with arthri-
tis. Using cartilage proteoglycan (PG)-induced arthritis (PGIA)
in BALB/c mice, we monitored serum levels of TSG-6 in corre-
lation with the onset and progression of arthritis and identified
TSG-6-positive cells in the joints. Although many connective
tissue cells were TSG-6-positive in the arthritic joints, unex-
pectedly, the strongest immunostaining of TSG-6 was
detected in the granules of mast cells that accumulated in
inflamed paws of mice. In vitro, rmTSG-6 bound to both
heparin and the mast cell-restricted tryptases, murine mast
cell protease-6 (mMCP-6) and mMCP-7, two major serine
proteases present in mast cell secretory granules (22). Further,
TSG-6 could be co-immunoprecipitated with both mMCP-6
and mMCP-7 from tissue extracts of arthritic paws, in which
the heavy chains (HC1 andHC2) of II were also present. These
data suggest that TSG-6maymodulatemast cell function via its
interactions with key components of secretory granules.
EXPERIMENTAL PROCEDURES
Reagents and Cell Culture—Chemicals were obtained from
Sigma-Aldrich or Fisher, and molecular biology grade reagents
were from Invitrogen. Recombinant human TSG-6 and
rmTSG-6, rmMCP-6 and rmMCP-7 were obtained from R&D
Systems (Minneapolis, MN), and cytokine ELISAs were from
either BD Biosciences or R&D Systems. Horseradish peroxi-
dase (HRP)-conjugated polyclonal antibodies (Abs) against
murine IgG and IgG2a and HRP-labeled rabbit anti-goat IgG
were purchased from BD Biosciences. Goat polyclonal Ab to
murine HC1 andHC2were obtained from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA), and goat Abs to mMCP-6 and
mMCP-7 were from R&D Systems. Chinese hamster ovary
(CHO-K1) cells were purchased from the American Type Cul-
ture Collection (ATCC; Manassas, VA), and murine CD44-
transfected CTLL-2 cells (CTLL-2/CD44) were kindly
donated by Robert Hyman (18). Unless noted otherwise, the
standard cell culture medium was DMEM, containing 4.5 g/li-
ter glucose and supplemented with 1% non-essential amino
acid solution, 1 mM sodium pyruvate, 1% L-glutamine, 100
mg/liter gentamicin sulfate, 0.5 M -2-mercaptoethanol, and
10% FBS (Hyclone, Logan, UT). All cell cultures were per-
formed in a humidified atmosphere of 5% CO2 in air at 37 °C.
Production and Purification of rmTSG-6 Fusion Protein—A
753-bp-long cDNA fragment of mouse IgG2a heavy chain was
obtained by reverse transcription of RNApurified from amAb-
producing murine B-cell hybridoma. The cDNA fragment was
amplified by PCR using primers with linkers for restriction
enzyme (EcoRI and BclI) cleavage sites. The 5-end of the
cDNA included the hinge region of the mouse IgG2a heavy
chain, and it was inserted into a Lonza pEE14.1 mammalian
expression vector (Lonza Biologics Ltd., Slough, UK) (Fig. 1A).
The stop codon of the full-length (828-bp)mouseTSG-6 cDNA
(23) in a pBlueScript S/K vector (Stratagene, La Jolla, CA) was
replaced with a sequence coding for the cleavage site of the
endopeptidase factorXa (Ile-Glu-Gly-Arg) followedwith a 9-bp
spacer before the EcoRI cleavage site (ATAGAAGGTCGT/
GACTCGAGG/GAATTC) at the 3-end of the TSG-6 cDNA.
Purified mTSG-6 cDNA was inserted into the EcoRI site
between the Lonza vector and the 5-end of the mouse IgG2a
heavy chain (Fig. 1A). Insert orientation was determined by
PCR, and the construct was sequenced. Semiconfluent
CHO-K1 cells were transfected with the mTSG-6-Xa-mFc2a
Lonza construct using CaCl2 precipitation according to a
standard protocol (24).
The Lonza expression vector contains a minigene encoding
glutamine synthase, an enzyme responsible for the biosynthesis
of glutamine (using glutamate and ammonia as substrates). The
transfected glutamine synthase gene (a part of the Lonza vec-
tor) can act as a selection tool in the presence of methionine
sulfoximine, and CHO cells containing the Lonza vector with
the glutamine synthase gene can survive in the absence of glu-
tamine and in the presence of 25–50 M methionine sulfoxi-
mine. Approximately 2 weeks after the transfection, individual
CHO colonies were transferred into 96-well cell culture plates.
Glutamine-free DMEM was replaced with CHO serum-free
medium (Lonza Inc., Mapleton, IL), and 48 h later, 100 l of
supernatant from each well was transferred to 96-well Max-
isorp ELISA plates (Nunc International, Hanover Park, IL) and
incubated overnight. Free binding sites of the wells were
blocked with 1% BSA, and the clones expressing the fusion pro-
tein (TSG-6-mFc2a) were identified withHRP-conjugated goat
anti-mouse IgG2a. Positive colonies were retested using
affinity-purified and biotinylated RC21 rabbit Ab raised against
mouse TSG-6 (5, 7, 25) followed by incubation with HRP-la-
beled streptavidin and tetramethylbenzidine substrate (TMB;
BDBiosciencesOptEiATMB substrate set). Cell lines secreting
the highest amounts of fusion protein were cloned using the
limiting dilution (0.5 cell/well) method and cultured in the
presence of irradiated (70 grays) mouse embryonic fibroblast
feeder cell layers. Positive colonies (retested by ELISA as
described above) were recloned by limiting dilution, and stable
clones, secreting high amounts of fusion protein, were sub-
jected to further testing.
The rmTSG-6-Xa-mFc2a fusion protein from the serum-
free supernatant of the CHO transfectant (clone 514) was puri-
fied on Protein G-Sepharose 4 Fast Flow (GE Healthcare)
according to the manufacturer’s instructions. The eluted prod-
uct was dialyzed against ultrapure H2O, lyophilized, and stored
at20 °C until further use. The purity of the fusion protein was
determined using SDS-PAGE with Coomassie Blue staining.
Western blots were performed with HRP-labeled goat anti-
mouse IgG2a or with affinity-purified and biotinylated rabbit
RC21 anti-TSG-6 antibody (7). Purified rmTSG-6-Xa-mFc2a
fusion protein was cleaved with factor Xa (200 units/mg pro-
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tein) in 2.5 ml of factor Xa cleavage/capture buffer (Novagen,
Madison,WI) (100mMNaCl, 50mMTris-HCl, 5mMCaCl2, pH
8.0) overnight at room temperature. The enzyme was removed
by Xarrest Sepharose (Novagen), and the IgG2a-Fc fragment
was absorbed onto Protein G-Sepharose.
After optimization of factor Xa cleavage, we tested the glyco-
sylation level of purified rmTSG-6 (clone 514). Twenty g of
purified protein was digested using a deglycosylation kit (Enzy-
matic DeglycoMx kit; QA-Bio LLC, Palm Desert, CA) contain-
ing a mixture of peptide:N-glycosidase F, O-glycosidase, siali-
dase, -galacosidase, and glucosaminidase, which removed all
N-linked and most of the O-linked oligosaccharides. The
digested product was loaded on 12% SDS-PAGE and trans-
ferred onto nitrocellulose membrane for immunostaining as
described above.
Testing of HA Binding and Enhancement of HA-CD44 Inter-
action by rmTSG-6—Binding of rmTSG-6 to immobilized HA
or heparin was tested using a microplate titration assay (sup-
plemental Fig. S1, A and B). In brief, rooster comb HA (Sigma)
was serially diluted in PBS (from 200 g/ml to 3.1 g/ml). One
hundred l of each HA solution was dispensed into duplicate
wells of 96-well Maxisorp plates and incubated overnight at
room temperature. Free binding sites were blocked with 1%
BSA. rmTSG-6 (from clone 514, free of IgG-Fc tail) was diluted
in PBS (concentration range, 0.031–2.0g/100l per well) and
incubated with theHA-coated wells for 2 h at 37 °C. HA-bound
rmTSG-6 was detected with biotinylated RC21 antibody, fol-
lowed by HRP-streptavidin and TMB substrate. rmTSG-6-me-
diated enhancement of HA binding to cell surface CD44 was
tested using murine CTLL-2/CD44 cells (18). Relative
amounts of cell surface-bound fluorescein-conjugatedHA (FL-
HA) in the presence or absence of rmTSG-6 were measured by
flow cytometry as described before (19). Briefly, HA-rmTSG-6
complexwas preformed by incubating FL-HAwith rmTSG-6 at
a 5:1 ratio (w/w) in PBS (pH 7.2) for 30 min at room tempera-
ture. The solution containing this complex was then added to
CTLL-2/CD44 cells and incubated for 1 h at 4 °C. Base-line
HA binding was determined by incubating the cells with the
same amount of FL-HA alone, and PBS alone served as the
background control. Cell surface fluorescencewas detected and
analyzed using a FACSCalibur flow cytometer and CellQuest
software (BD Biosciences) (19) (supplemental Fig. S1C).
TSG-6-specific Monoclonal Antibody (mAb) Production and
Development of Capture ELISA—Togeneratemurine B cells for
hybridoma fusion and subsequent TSG-6-specific mAb pro-
duction, we used rmTSG-6 to immunize TSG-6-deficient
BALB/cmice (21) (now available fromThe Jackson Laboratory;
stock number 012903). All animal experiments were approved
by the Institutional Animal Care and Use Committee of Rush
University Medical Center (Chicago, IL). The TSG-6-deficient
BALB/c mice were immunized intraperitoneally with 50 g of
purified rmTSG-6 emulsified with 2 mg of dimethyldioctade-
cyl-ammonium bromide (DDA) adjuvant in a total volume of
100 l of PBS. Peripheral blood samples were taken after the
third injection, and anti-TSG-6 serum titers were determined
by ELISA (using immobilized rmTSG-6 as the antigen and
HRP-conjugated anti-mouse IgG for detection). Spleen cells
from positive mice were fused with the Sp2/0-Ag14 myeloma
cell line (ATCC) employing a standard protocol (26, 27), and
mAb-producing hybridomas were selected by ELISA. Positive
hybridomas were repeatedly cloned by limiting dilution, and
ascites fluid was produced in BALB/c mice after hybridoma
injection. The isotypes and light chains of eachmAbwere iden-
tified using amouse IgG isotype determination kit (SantaCruz).
Immunoglobulin fractions of five hybridoma clones (desig-
nated NG2, NG3, NG4, NG5, and NG8) were purified on pro-
tein G columns, and a portion of each was biotinylated and
tested for cross-reactivity using a standard inhibition ELISA
(27). In brief, 0.1 g of rmTSG-6 was coated to each well, and
serial dilutions of purified anti-TSG-6 mAbs were mixed with
optimally diluted aliquots of each biotinylated anti-mTSG-6
mAb. Recombinant mouse and human TSG-6 proteins (R&D
Systems) were used as additional positive controls and for the
in-house development of new murine and human TSG-6 cap-
ture ELISA systems employing non-cross-reactive pairs of anti-
TSG-6 mAbs. Purified mAb NG3 (IgG2b ) was used for the
capture of either murine or human TSG-6. Biotinylated NG8
mAb (IgG1 ) was employed for the detection of murine
TSG-6, and NG4 (IgG1 ) was used for the detection of human
TSG-6 (an example of the standard curve of murine TSG-6
ELISA is shown in supplemental Fig. S1D). The sensitivity of
capture ELISAs ranged from 500 pg/ml to 200 ng/ml TSG-6.
Immunizationwith Cartilage PGAggrecan andAssessment of
Arthritis—Human osteoarthritic cartilage was obtained from
patients undergoing knee joint replacement surgery. The col-
lection of cartilage from consenting patients was approved by
the Institutional Review Board of Rush University Medical
Center. PG isolation from osteoarthritic cartilage and deglyco-
sylation of PG have been described in detail (28, 29). Female
BALB/c mice of 16–24 weeks of age were purchased from the
NCI-Frederick, National Institutes of Health. A standard pro-
cedure was applied for induction of PGIA in BALB/c mice (29).
In brief, 100 g of core protein of PG was emulsified with 2 mg
ofDDA inPBS (pH7.4) and injected intraperitoneally at 3-week
intervals (days 0, 21, and 42). Control animals received PBS
emulsifiedwithDDA.Arthritis severity was determined using a
visual scoring system based on the degree of swelling and red-
ness of the front and hind paws (29, 30). Animals were exam-
ined at least three times a week; the degree of inflammationwas
scored from 0 to 4 for each paw, resulting in a cumulative
arthritis score ranging from 0 to 16 for each animal (29, 30). All
mice were scored by two different investigators in a blinded
manner. The incidence of arthritis was expressed as the per-
centage of immunized mice that were arthritic. Upon sacrifice,
limbs were removed, fixed in 10% formalin, acid-decalcified,
embedded in paraffin, and processed according to standard his-
tological procedures (29–31). Serum cytokines IL-1, IL-6,
IL-17, andTNF-were quantified using commercially available
ELISA kits.
Preparation of Synovial Fluid and Tissue Extracts, Histology,
and Immunohistochemistry—Blood and tissue samples were
collected from the animals at different time points of immuni-
zation, prior to and after the onset of arthritis (5, 30, 32, 33).
Synovial fluid from arthritic ankle joints (with the highest
arthritis score of 4) was harvested immediately after euthanasia
(34) in 20 l of PBS/joint and centrifuged at 5,000 rpm for 10
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min, and the supernatant was stored at 70 °C until use. For
preparation of tissue extracts, the skin was removed from
arthritic or normal paws, and the tissues of ankle and tarso-
metatarsal joints (including bone) were dissected and placed in
cold radioimmune precipitation assay lysis buffer containing a
Halt protease inhibitor mixture (both from Pierce). Homoge-
nates were prepared by ultrasonication (Virsonic Digital 50,
VirTis, Gardiner, NY) for 90 s on ice and centrifuged at 5,000
rpm. Protein contents of the supernatants of tissue extracts
were measured using the bichinconic acid assay (Pierce).
For histology, macroscopically similar paws were dissected,
fixed in 10% formalin, decalcified, and embedded in paraffin.
Deparaffinized sections were stained with hematoxylin and
eosin, toluidine blue, or safranin O. For immunohistochemis-
try, paws with similar degrees of arthritis were embedded in
optimal cutting temperature medium, frozen, and sectioned
with a tungsten knife at32 °C in aMICROMHM550 cryostat
(MICROMInternational,Walldorf, Germany). Frozen sections
were immunostained with mAbs to TSG-6 or goat Abs to the
mouse tryptases mMCP-6 andmMCP-7. Non-immune goat or
mouse IgG served as a background control.
In Vitro Detection of Interactions of TSG-6 with HA or Hepa-
rin and Mast Cell Tryptases—Using ELISA-based systems for
the detection of HA- or heparin-bound proteins (TSG-6 and
the mast cell tryptases mMCP-6 and mMCP-7), optimal con-
centrations of rooster comb HA or heparin (both from Sigma);
rmTSG-6, rmMCP-6, and rmMCP-7; and Abs against TSG-6
and mMCP-6 and mMCP-7 were determined in preliminary
experiments. To detect a tripartite interaction ofHAor heparin
with TSG-6 and tryptases, we developed a triple layer sandwich
microplate assay. In brief, 2 g of HA in 100 l of PBS (first
layer) was coated onto the wells of Maxisorp (Nunc) plates
overnight at room temperature. Heparin (10 g) in 1% N-(3-
dimethylaminopropyl)-N-ethyl-carbodiimide hydrochloride
was dissolved in H2O and coated onto the wells of CovaLink
(Nunc) plates overnight at 37 °C (35). After blocking the free
binding sites with 5%BSA, the wells were incubatedwith 0.1g
of rmTSG-6 (second layer) for 1 h at 37 °C, followed by incuba-
tion with rmMCP-6 or rmMCP-7 (third layer; concentration
range, 0.025–0.2 g/well). The third layer of bound tryptases
was detected with anti-mMCP-6 and anti-mMCP-7 Abs.
Reciprocally, rmMCP-6 or rmMCP-7 was used as a second
layer, and rmTSG-6 was used as the third layer (at the concen-
trations described above), followed by detection of bound
rmTSG-6 with biotinylated NG8mAb. In each assay, reference
wells contained only a single protein (TSG-6 or tryptase), and
immobilized proteins detected with the irrelevant Ab
(rmTSG-6 with anti-tryptase Abs and vice versa) served as
background controls. Reactions were developed with HRP-
conjugated secondary reagents and TMB substrate, and values
were expressed as the absorbance measured at 450 nm using a
Synergy 2 ELISA reader (BioTek Instruments, Winooski, VT).
Identification of Mast Cell Tryptases byWestern Blotting and
Co-immunoprecipitation of Tryptases and HCs of II with
TSG-6—Tissue extracts were prepared from arthritic and non-
arthritic paws as described above, and 50g of each was loaded
onto 12% SDS-PAGE, along with 0.2 g of rmTSG-6, 0.1 g of
rmMCP-6, and 0.05 g of rmMCP-7. The proteins were
resolved under reducing conditions, transferred to a nitrocel-
lulose membrane, and probed with different antibodies:
affinity-purified biotinylated rabbit RC21 anti-TSG-6 Ab, anti-
MCP-6, or anti-MCP-7. In most cases, membranes were
stripped and reprobed with another antibody to detect comi-
gration of the two proteins. The supernatants of paw extracts
were subjected to Western blotting with or without immuno-
precipitation as described (18, 36).
For co-immunoprecipitation, supernatants of paw extracts
(200 g of protein of each) were preabsorbed with Protein
G-Sepharose, washed, and then incubated with 10g of TSG-6
mAbmixture (NG3, NG4, NG5, andNG8; 2.5g of each) over-
night at 4 °C on a rotary shaker. Immune complexes were
absorbed to Protein G-Sepharose for 30 min at room tempera-
ture, washed, and boiled in reducing buffer. One-third of each
sample was loaded on 12% SDS-PAGE, and proteins were sep-
arated under reducing conditions. The proteins were trans-
ferred onto nitrocellulose membrane and stained with biotin-
ylated Abs to TSG-6 (RC21 or NG8) or with goat antibodies to
HC1 or HC2 (both at 1:500 dilution) or goat antibodies to
mMCP-6 or mMCP-7 (both at 1:2,000 dilution) followed by
HRP-conjugated rabbit antibody to goat IgG (Invitrogen;
1:5,000 dilution). HRP-labeled mouse mAb to -actin (Invitro-
gen; 1:5,000 dilution) was used to ensure that equal amounts of
cell extracts were loaded. All incubations were performed at
room temperature for 1–2 h. Positive protein bands were
detected by ECL (Amersham Biosciences).
Statistical Analysis—Data were analyzed using Student’s
t-tests to compare two groups or analysis of variance with the
least significant difference post hoc test for comparison of mul-
tiple groups. Spearman’s  test was used to determine correla-
tion between two sets of data. p values of 0.05 were consid-
ered statistically significant. All analyses were performed using
the SPSS (version 16.0) statistical software package (SPSS, Chi-
cago, IL).
RESULTS
Production, Purification, and Cleavage of Recombinant
Mouse TSG-6 (rmTSG-6) Fusion Protein—The first goal of this
study was to develop a simple expression system for high yield
production of functionally active rmTSG-6. The schematics of
the construct used for CHO cell transfection are shown in Fig.
1A, and the stepwise cloning method is described under
“Experimental Procedures.” Positive selection of transfectants,
followed by a limiting dilution cloning procedure and a direct
ELISA system using either a tag-specific (mouse IgG2a-Fc) or a
protein-specific (TSG-6) Ab, allowed us to select clones with
the highest yield of the fusion protein. Real-time PCR con-
firmed the presence of 80 copy numbers using the template
of genomic DNA of the CHO transfectant, and0.8–1.2mg of
recombinant fusion protein could be purified from 100 ml of
conditioned medium of clone 514.
The purity of the rmTSG-6-Xa-mFc2a fusion protein (72
kDa) and rmTSG-6 (39 kDa after cleavage with factor Xa and
repurification on Protein G-Sepharose), were over 95%,
although some degradation occurred during the enzymatic
cleavage and repeated purification (Fig. 1, B–D). Because
rmTSG-6was synthesized byCHOcells in serum-freemedium,
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serum immunoglobulins and II could not affect the purity
(first and second lanes in Fig. 1, B–D) or the functionality of
secreted rmTSG-6. The molecular mass of purified rmTSG-6
after Xa cleavage was39 kDa (instead of30 kDa), indicating
that the CHO cell-secreted rmTSG-6 was glycosylated (Fig. 1,
B–D, second lanes). Indeed, enzymatic removal of all N-linked
and most O-linked oligosaccharides reduced the mass of
rmTSG-6 to the expected 30 kDa size (third lanes, Fig. 1,
B–D). The Fc-free rmTSG-6 was largely water-insoluble but
could be solubilized by the addition of 5% BSA and dialysis
against serum-free CHO medium. Purified rmTSG-6 bound
HA in a concentration-dependent manner, and, similar to
recombinant human TSG-6 (19), it enhanced the binding of
fluorescence-labeled HA to cell surface CD44 (supplemental
Fig. S1C). rmTSG-6 was used for immunization of TSG-6-de-
ficient mice and subsequent generation of TSG-6-specific
mAbs (clones NG2, NG3, NG4, NG5, andNG8). rmTSG-6 also
served as a reference standard (supplemental Fig. S1D) for the
development and use of mouse (and human) TSG-6 ELISA
systems.
Serum TSG-6 Concentrations Correlate with Arthritis Sever-
ity and Serum Levels of Proinflammatory Cytokines but Not
with Immune Responses in PGIA—Purified rmTSG-6 and opti-
mally paired mAbs were used to measure TSG-6 concentra-
tions in serum and synovial fluid samples and in tissue extracts
of inflamed joints of BALB/cmice immunizedwith cartilage PG
on days 0, 21, and 42 to induce PGIA. SerumTSG-6 reached the
maximum levels by day 61 of immunization, around the time
when the acute joint inflammation (swelling, redness, and cell
infiltration) also reached the maximum (Fig. 2, A and 3). How-
ever, whereas joint inflammation (arthritis score) declined
slowly (Fig. 2A, solid diamonds), serum TSG-6 concentrations
declined more rapidly (Fig. 2A, solid squares). Low levels of
TSG-6 could also be detected in the serum of PBS/DDA-in-
FIGURE 1. Schematics of the mammalian expression vector containing
the rmTSG-6 fusionprotein andanalysis of purified rmTSG-6.A, structure
of the mammalian expression vector (Lonza pEE14.1-rmTSG-6-Xa-mFc2a)
incorporating the fusion protein. Shown is detection of rmTSG-6 by SDS-
PAGE and Coomassie Blue (CB) staining (B) and Western blotting (WB) with
affinity-purified and biotinylated RC21 polyclonal rabbit anti-TSG-6 antibody
(C) and monoclonal mouse anti-TSG-6 antibody (clone NG8) (D). The lanes
were loadedwith rmTSG-6 in the sameorder. Lane 1, the 72-kDa rmTSG-6-Xa-
mFc2a fusion protein purified from CHO serum-free medium (a CHO line
transfected with pEE14.1-rmTSG-6-Xa-mFc2a and cloned as described); lane
2, purified rmTSG-6 (39kDawithout themFc2a-tail) after factor-Xa cleavage
and repurification on protein G-Sepharose; lane 3, the same rmTSG-6 as
shown in lane 2 but after deglycosylation (30 kDa) using a kit containing
peptide:N-glycosidase F, O-glycosidase, sialidase, -galactosidase, and glu-
cosaminidase. B, the TSG-6 proteins were loaded on 12% SDS-PAGE (20 g
protein/lane), run under reducing conditions and stained with Coomassie
Blue (CB). C and D, the separated proteins (1 g/lane) were transferred to
nitrocellulose membrane and probed with biotinylated RC21 and NG8 anti-
bodies, respectively, followed by HRP-streptavidin. Molecular mass is indi-
cated in kDa.WB, Western blot.
FIGURE 2. Correlation between arthritis severity and serum TSG-6 levels
at different time points during the development of PGIA. A, mice immu-
nized with human cartilage PG in DDA adjuvant were scored for arthritis
severity twice a week after the second immunization (week 21), and serum
was collected weekly up to day 75 after the first immunization. Control
groups were injected with PBS/DDA emulsion. Arthritis scores on the left Y
axis, and serum TSG-6 concentrations on the right y axis are shown at five
selected time points of immunization. Data shown are the mean S.E. (error
bars) (n 10mice/group/time point). Statistically significant differences (p
0.001) between the PGIA and PBS/DDA-injected groups from the indicated
time point are depicted with arrows. Data were analyzed using repeated
measures analysis of variance. B, correlations between serumTSG-6 levels are
indicatedbySpearman’svalues andcorrespondingpvalues at fourdifferent
time points after the first PG/DDA immunization.
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jectedmice (open squares in Fig. 2A), whichwas probably due to
the activation of innate immune cells at the injection site (peri-
toneal cavity) (32). Thus, the amount of TSG-6 in serum can be
regarded as an indicator of preinflammatory and inflammatory
processes (37) and appears to be a more reliable “biomarker” of
the severity of acute disease than the levels of proinflammatory
cytokines in PGIA (Table 1). The correlation between arthritis
score and serum TSG-6 was not significant at the early stage of
disease (day 54) but became significant at the peak of arthritis
(day 61) and remained such during progression toward chronic
disease (Fig. 2B and Table 1). However, TSG-6 became unde-
tectable in serum samples harvested frommice at late stages of
PGIA (120–150 days after the first immunization), when acute
synovial inflammation had given way to pathologic joint
remodeling, leading to deformities and loss of function (data
not shown).
Whereas serum TSG-6 concentrations showed a strong pos-
itive correlation with arthritis severity from day 61 to 75 after
the first immunization (Fig. 2A and Table 1), serum levels of
other “arthritis signature” proinflammatory cytokines (such as
IL-6, IL-17, and TNF-) correlated with the arthritis scores and
serum TSG-6 at the acute or subacute phase (day 61 or 69) of
PGIA, whereas serum IL-1 concentrations increased in
response to immunization and subsequent arthritis onset but
did not seem to correlate with disease severity or serum TSG-6
(Table 1). We could not detect any correlation between serum
TSG-6 levels and the concentrations of anti-PGAbs in serumor
the magnitude of PG-specific T-cell responses (data not
shown).
TSG-6 in Synovial Fluid and Tissue Extracts of Inflamed
Joints of Mice with PGIA—As illustrated in the histology panel
in Fig. 4A, at an advanced stage of acute arthritis (61 days after
the first immunization), the involved paws were heavily infil-
trated by inflammatory cells and also showed histological evi-
dence of cartilage and bone destruction. At this stage of PGIA,
we harvested synovial fluid from arthritic ankle joints and pre-
pared tissue extracts from the inflamed paws for measurement
of TSG-6 content by ELISA andWestern blotting. The amount
of TSG-6 in pooled samples of synovial fluidwas 110 7 pg/mg
protein, and it ranged from 20 to 550 pg/mg protein in the
extracts of inflamed paws and from 0 to 60 pg/mg protein in
non-arthritic control paws, as determined by ELISA. Western
blotting demonstrated the presence of TSG-6 in both synovial
fluid and tissue samples (Fig. 3A). In both cases, TSG-6 was
found mostly in the form of high molecular weight complexes
(most likely composed ofTSG-6 and a heavy chain (HC1 and/or
FIGURE 3. Western blot analysis of TSG-6 in synovial fluid and in tissue
extracts of inflamed paws of mice with PGIA. A, the Coomassie Blue (CB)-
stained strips represent total protein from synovial fluid (first lane) or tissue
extracts of arthritic paws (first and second lanes in the left panel under Paw
extracts), harvested on the peak of arthritis (day 61). Pooled synovial fluids (50
l) after digestionwith Streptomyces hyaluronidase or from 2mg (lane 1) and
4mg (lane 2) of protein of paw extracts from arthriticmicewere separated by
12% SDS-PAGE. Lane 3 contains 1g of purified rmTSG-6 protein (*) (without
Fc2a tail). TSG-6 was detected with biotinylated RC21 antibody. The arrows
point to the high molecular mass (120-kDa) TSG-6 complex and free (39-
kDa) TSG-6 (B) Western blot analysis of TSG-6 and the heavy chains (HC1 and
HC2) of II in tissue extracts of inflamed paws. Tissue extracts from two
arthritic paws were loaded on 12% SDS-PAGE (20 g of protein/lane). The
proteins were transferred onto a nitrocellulose membrane, probed with
mAbs toTSG-6and-actin, and then strippedand sequentially reprobedwith
RC21 anti-TSG-6 antibody, anti-HC1, and anti-HC2 antibody, respectively. The
arrowspoint to the TSG-6-containing complexes (no free TSG-6was detected
in this case) and to -actin (loading control).WB, Western blot.
TABLE 1
Serum TSG-6 and cytokine concentrations and their correlation with arthritis and/or serum TSG-6 levels at selected time points in PGIA
The numbers in the first rows indicate mean S.E. of TSG-6 or cytokine concentrations (pg/ml) in serum at five selected time points (days 38, 54, 61, 69, and 75 after the
first PG immunization) (n 10mice). Numbers in parentheses in italic type (Spearman’s correlation coefficient/corresponding p value) in the second and third rows depict
significant correlation with serum TSG-6 levels and arthritis score, respectively. NS, correlation is not significant.
Day 38 Day 54 Day 61 Day 69 Day 75
TSG-6 0.0 5.59 1.31 16.6 2.45 7.34 1.06 5.77 0.57
Arthritis (NS) (NS) (0.631/0.050) (0.864/0.001) (0.845/0.002)
IL-6 6.68 0.68 17.5 1.57 19.18 3.29 14.30 0.85 15.65 1.01
TSG-6 (NS) (NS) (0.760/0.017) (NS) (NS)
Arthritis (NS) (NS) (0.720/0.029) (NS) (NS)
IL-17 0.61 0.39 5.27 0.74 7.54 1.30 5.35 0.47 4.81 0.20
TSG-6 (NS) (NS) (0.894/0.007) (NS) (NS)
Arthritis (NS) (NS) (0.935/0.002) (NS) (NS)
TNF- 1.38 0.51 9.27 0.77 9.28 0.39 8.34 1.14 8.25 0.31
TSG-6 (NS) (NS) (NS) (0.841/0.018) (NS)
Arthritis (NS) (NS) (NS) (0.741/0.057) (NS)
IL-1 7.40 0.92 9.50 1.23 9.20 1.20 9.31 0.96 7.85 0.89
TSG-6 (NS) (NS) (NS) (NS) (NS)
Arthritis (NS) (NS) (NS) (NS) (NS)
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HC2) of II (3, 25)); only small amounts of the free form could
be detected (Fig. 3A). Interestingly, synovial fluid contained a
single TSG-6-positive band at 120–125 kDa, whereas the
extracts of inflamed paws showed multiple bands below that
size (Fig. 3A, lanes 1 and 2). A Western blot of paw extracts
revealed two TSG-6 bands at125 and80 kDa, respectively
(Fig. 3B). Both of these bands were also recognized by an anti-
mouse HC1 Ab, but only the upper band was recognized by
anti-HC2 Ab (Fig. 3B).
Cellular Localization of TSG-6 in the Inflamed Paws of Mice
with PGIA—Using immunohistochemistry on frozen sections
of arthritic hind limbs (similar to that shown in Fig. 4,A and B),
we could detect TSG-6 inmost of the cells of the inflamed tissue
(Fig. 4, C andH). Unexpectedly, the strongest immunostaining
FIGURE 4.Histology of the inflamedpawonday 61 of PGIA and localization of TSG-6 in inflamed tissue andmast cells. A, the entire ankle-paw region of
an arthritic hind limb is shown in a low magnification montage picture. The section was stained with H&E. The arrows depict areas of cartilage and bone
destructionby inflammatory synovium, and the area fromwhich synovial fluidwas harvested is also indicated.B, a highmagnification insert at thebottom right
corner represents inflamedperiarticular tissuewhere TSG-6-positive cells (includingmast cells) were found in frozen sections of hind limbswith similar arthritis
scores. C, immunostaining of inflamed tissue with anti-TSG-6 mAbs (red fluorescence) identified several TSG-6-expressing cells (nuclei were stained blue).
D, mast cells, which showed strong and distinct immunostaining for TSG-6 in their secretory granules, were identified by toluidine blue (E), safranin O (F), and
anti-mousemast cell protease (G) (mMCP-6; mast cell tryptase) staining. In areas similar to that framed in B TSG-6 (red) (H) andmMCP-6 (green) (I) co-localized
in mast cells as shown in the overlaid image (yellow) (J).
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appeared to be localized within large, granulated cells (Fig. 4D).
Such cells also showed metachromatic staining with toluidine
blue (Fig. 4E) and red staining with safranin O (Fig. 4F), indi-
cating that they could be connective tissue mast cells. To fur-
ther identify this cell type, we used an Ab against the mast
cell-restricted tryptase mMCP-6 for immunostaining of tissue
sections. Indeed, anti-TSG-6 (Fig. 4H) and anti-mMCP-6 (Fig.
4, G and I) Abs both stained the same type of cell. Co-localiza-
tion of TSG-6 (Fig. 4H, red) and mMCP-6 (Fig. 4I, green) was
further confirmed by the overlay of images (Fig. 4J, yellow) of
sections simultaneously stained with fluorescent Abs against
the respective molecules.
HA Is a Stronger Competitor Than Heparin for TSG-6 Bind-
ing—rmTSG-6 bound to either HA- or heparin-coated plates,
although the amount of TSG-6 bound to heparin appeared to
be less than the amount that bound to HA. This difference
might be due to the different molecular mass of HA versus hep-
arin or different affinity of TSG-6 with HA or heparin (10).
Although TSG-6 binding sites to HA and heparin are different
(10, 38), and an octasaccharide of HA is sufficient to bind
TSG-6, these twoGAGsmay compete for and/or interfere with
TSG-6 binding either in vivo or in vitro. In a competitive inhi-
bition assay, we compared how HA or heparin could compete
for TSG-6 binding (Fig. 5). Indeed, whereas the in vitro pre-
formed TSG-6heparin complex could not inhibit TSG-6 bind-
ing toHA, the in vitro preformed TSG-6HA complex inhibited
TSG-6 binding to heparin. The controls showed that the TSG-
6HA complex inhibited binding toHA, and the TSG-6heparin
complex inhibited the TSG-6 binding to heparin (Fig. 5).
TSG-6 Binds Mast Cell Tryptases in the Presence of Heparin
or HA—Co-localization of TSG-6 andmMCP-6 inmast cells in
inflamed joint tissue suggested that TSG-6 might be stored in
mast cell granules, which are known to contain tryptases
(mMCP-6 (22) and mMCP-7 (39)) and heparin (40). Among
other constituents, TSG-6 has been shown to bind eitherHA (1,
8) or heparin (10). In addition, TSG-6 can form a ternary com-
plex with II in the presence of HA (3) or heparin (10). There-
fore, it was of interest to determinewhether TSG-6 could inter-
act with mast cell tryptases in a similar manner in vitro.
rmTSG-6, prebound toHA, could bind rmMCP-6 or (to a lesser
extent) rmMCP-7, but this was not the case with TSG-6 pre-
bound to heparin (Fig. 6A). In a reciprocal system, rmMCP-6
FIGURE 5. Competitive inhibition assay of TSG-6 binding to HA and hep-
arin. Theoptimal rangeof TSG-6binding toHA- or heparin-coatedplateswas
determined and then a competitive inhibition assay was performed. Three
different concentrations were used for coating (2.5, 5, and 10g of HA or 5.0,
10, and 20g of heparin), and four different concentrations of TSG-6 in dupli-
cate wells were assayed simultaneously in two plates. TSG-6 alone (50 ng in
100l of 0.5% BSA/PBS, closed columns), or the same amounts of TSG-6 were
preincubated with HA or heparin (amounts of these GAGs are indicated) for
2 h at 37 °C prior to transferring to either HA- or heparin-coated wells. TSG-6-
binding was detected with biotinylated mAb NG8, and the reaction was
developed with TMB substrate. Heparin only slightly inhibited or did not
inhibit the binding of TSG-6 to HA, whereas HA could significantly inhibit
TSG-6binding toheparin (in a concentration-dependentmanner). Significant
differences are indicatedwithasterisks (*,p0.05; **,p0.01). Error bars, S.E.
FIGURE6.Measurementof theassociationof rmTSG-6withmast cell tryp-
tases (rmMCP-6 or rmMCP-7) and HA or heparin in vitro. The graphs rep-
resent the relative amounts of bound rmMCP-6 or rmMCP-7 after incubation
of 0.1 g of rmTSG-6/well with immobilized HA or heparin and the subse-
quent addition of various amounts of rmMCPs (concentrations are indicated
at the top) (A) and the relative amounts of bound rmTSG-6 after incubation of
rmMCP-6 or rmMCP-7 (at concentrations indicated at the top) with HA or
heparin and the subsequent addition of rmTSG-6 (0.1 g/well) (B). Immobili-
zation of HA and heparin and subsequent binding and detection of com-
plexes formed between rmTSG-6 and rmMCP-6 or between rmTSG-6 and
rmMCP-7 are described in detail under “Experimental Procedures.” Base-line
values (absorbance values resulting from direct binding of either TSG-6 or
mMCPs to either HA or heparin) are indicated with empty columnswith an X,
and thebase-line levels are indicatedwithhorizontal broken lines.Mean S.E.
values (error bars) of duplicate samples of three independent experiments are
shown. Significant differences are indicatedwith asterisks (*, p 0.05; **, p
0.01).
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and rmMCP-7, bound to either HA or heparin, could bind
TSG-6 (Fig. 6B).
TSG-6 Can Be Co-immunoprecipitated with Mast Cell Tryp-
tases fromTissue Extracts of Arthritic Joints—TSG-6,mMCP-6,
and mMCP-7 were present in relatively high amounts in tissue
extracts of inflamed paws but were detected in lower amounts
in tissue extracts of non-inflamed paws (Fig. 7, A–C). TSG-6
could be co-immunoprecipitated with both tryptases (espe-
cially with mMCP-6) (Fig. 7, D–F), suggesting that complex
formation between TSG-6 and mast cell tryptases (most likely
via HA or heparin binding in secretory granules) did occur in
vivo under inflammatory conditions.
DISCUSSION
The beneficial effects of TSG-6 treatment have been de-
scribed in different murine models of rheumatoid arthritis
(5–7, 41), and the protective function of this protein is consis-
tent with the development of more severe arthritis in TSG-6-
deficient mice than in wild type mice upon immunization with
cartilage PG (21). In adoptively transferred PGIA, TSG-6 gene
expression was detected in synovial tissue of recipient mice
before the clinical symptoms of arthritis developed (37), and
TSG-6 was also described as a signature gene of early inflam-
matory events in a number of other diseases (for more details,
see reviews (42, 43)). However, no systemic studies have been
carried out to investigate the kinetics of TSG-6 production dur-
ing the development and progression of any inflammatory joint
disease, including rheumatoid arthritis.
As a first step of generating a highly sensitive assay, we con-
structed an expression vector that contained both TSG-6 and
mouse IgG2a-Fc fusion partner cDNA, separated by an endo-
protease cleavage site (Ile-Glu-Gly-Arg) specific for factor Xa
(which converts prothrombin to thrombin).We also developed
a stepwise cloning procedure for rapid selection of CHO trans-
fectants with the highest yield of rmTSG-6 fusion protein
released into serum-free medium. rmTSG-6 protein was then
used to generate B cell hybridomas from TSG-6-deficient mice
(21) and to select pairs of mAbs for capture ELISAs, where
rmTSG-6 could also be employed as a reference standard. Some
of the anti-TSG-6mAbs were also suitable for immunoprecipi-
tation, Western blotting, and immunohistochemistry. With
this repertoire of detection tools, we immunized BALB/c mice
with cartilage PG to induce PGIA, with the goals to determine
the kinetics of serum TSG-6 levels in correlation with arthritis
severity and other disease markers and to detect the accumula-
tion of this protein at the site of inflammation.
Serum TSG-6 concentrations showed significant positive
correlation with the progression of arthritis (Fig. 2). In this
regard, TSG-6 appeared to be a better biomarker of joint
inflammation than the arthritis-related proinflammatory cyto-
kines IL-6, IL-17, TNF-, and IL-1, which showed correlation
with the disease development only at certain time points or not
at all (Table 1). Serum TSG-6 levels declined when arthritis
progressed toward the chronic phase (Fig. 2), during which
massive tissue destruction (Fig. 4) was followed by synovial
fibrosis and bone remodeling (21, 31). We could accurately
measure TSG-6 levels in synovial fluid samples and tissue
extracts of severely inflamed paws of mice. Western blots car-
ried out on these samples revealed that the majority of TSG-6
was present as a high molecular weight species (Fig. 3), indicat-
ing that at these inflammatory sites, TSG-6 was probably com-
plexed with HCs from II, as described before (3, 7). The
inflammatory paw extracts consistently contained both a
125-kDa species (probably a TSG-6HC1 and a TSG-6HC2
complex) (Figs. 3 and 7) and an80-kDa species (Fig. 3B). The
latter band could be a degradation product of the TSG-6HC1
complex and was not detected in synovial fluids of arthritic
joints.
For the first time, we were able to immunolocalize TSG-6-
producing cells in acutely inflamed joint tissues of mice using
the newly generated mAbs. Whereas most cells in the arthritic
joints stained positively for TSG-6 at low to moderate levels,
very high amounts of TSG-6 proteinwere detected in the secre-
tory granules ofmast cells,most of which cells showed evidence
of activation (degranulation) in the inflamed tissue (Fig. 4).
Beyond metachromatic and positive safranin O staining, we
sought to identify these cells more precisely by employing Abs
to mouse mast cell-specific proteins. An Ab against the mast
cell-specific tryptase mMCP-6 (also a component of secretory
granules) gave a signal that overlapped with TSG-6-specific
staining, indicating colocalization of these two proteins inmast
cell granules (Fig. 4).
FIGURE 7.Western blots of TSG-6 andmast cell tryptases in arthritic and
normalpawextracts andco-immunoprecipitationof in vivo formedTSG-
6-tryptase complexes.A–C,Westernblots show the samemembrane,which
was stained with an antibody to TSG-6 (A) and then stripped and restained
with antibodies to mMCP-6 (B) and mMCP-7 (C), respectively. The laneswere
loaded with samples as follows: 0.2 g of purified rmTSG-6, 0.1 g of recom-
binant mMCP-6, tissue extract (50 g of protein) from arthritic mouse paw
(Arthr), extract (50gof protein) fromnormal control paw (Cntrl), and 0.05g
of mMCP-7. D–F, extracts of arthritic (left lanes) or normal (right lanes) mouse
paws were immunoprecipitated (IP) with a mixture of anti-TSG-6 mAbs (as
describedunder “Experimental Procedures”) and thenblotted (WB) with anti-
TSG-6 (RC21) (D), anti-mMCP-6 (E), and anti-mMCP-7 antibodies (F). The
arrows point to the highest and lowest molecular weight TSG-6 species in D.
The broken arrow indicates the TSG-6 coimmunoprecipitated mMCPs.
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The fact that bothmMCP-6 (22, 39) andTSG-6 (10) can bind
heparin prompted us to investigate whether TSG-6 could asso-
ciate with mMCP-6 via heparin. Indeed, our in vitro studies
revealed a tripartite association of rmTSG-6 with rmMCP-6
(and, to a lesser extent, with rmMCP-7) through heparin as well
as through HA (Fig. 6). mMCP-6 and, to a lesser extent,
mMCP-7 could be pulled down by TSG-6 immunoprecipitates
of arthritic paw extracts (Fig. 7), suggesting that these proteins
were associated (or formed a complex) in vivo under the condi-
tions of joint inflammation.
Mast cells constitute the first line of defense in various IgE-
mediated allergic reactions and helminth infections, and they
are strategically positioned near blood vessels, which enables
them to capture allergen-specific IgE, IgG, or other substances
from both blood and tissue (44). Mast cell secretory granules
contain proteases, GAGs, and proinflammatory cytokines that
are released into extracellular matrix upon degranulation (22).
Tryptases, such asmMCP-6 andmMCP-7 (murine orthologs of
human -tryptases), are the predominant serine proteases
stored in mast cell secretory granules (45). These enzymes are
tightly packaged in complexes with serglycin PGs through elec-
trostatic interactions between their positively charged amino
acid residues and the negatively charged GAG (heparin or
chondroitin sulfate E) side chains of serglycin (39, 45). In addi-
tion to packaging, heparinmay play a role in themaintenance of
tryptases in an active conformation at low pH inside the mast
cell granules, but proteolytic activity increases at neutral pH
after release of the tryptase-heparin complexes into the extra-
cellular environment (39, 45).
The presence of TSG-6 in mast cells has not been reported.
Here we have found that the tryptases mMCP-6 and mMCP-7,
upon binding to eitherHAor heparin, associatewithTSG-6. As
noted above, HA-bound TSG-6 has a stronger association with
both tryptases than heparin-bound TSG-6 (Fig. 6). Some of the
differences between HA- and heparin-bound complexes might
be explained with the better adsorption of highmolecular mass
HA (1,000–2,000 kDa) than low molecular mass heparin
(12–15 kDa) to plastic surfaces. However, in a competitive inhi-
bition assay (Fig. 5), we found that HA inhibited the binding of
rmTSG-6 to heparin, but heparin did not inhibit the binding of
rmTSG-6 to HA. Nonetheless, enhancement of TSG-6-tryp-
tase interactions on the GAG-coated surfaces is obvious under
the conditions of our in vitro assays (Fig. 6). Moreover, co-
immunoprecipitation of TSG-6 and tryptases (Fig. 7) suggests
that complex formationmay also occur in vivo. However, more
extensive studies are required to specify the type of molecular
interactions among HA, heparin, TSG-6, and tryptases.
What could be the relevance of these tripartite interactions
to pathophysiological events involving mast cells? As men-
tioned before, TSG-6 readily forms a covalent complexwith the
HC1 or HC2 subunit of the serine protease inhibitor II (com-
posed of two HCs bound to the chondroitin sulfate chain on
bikunin, a Kunitz type protease inhibitor) and augments the
inhibitory capacity of this molecule (3). Recent studies indicate
that potentiation of II activity is achieved by the TSG-6-me-
diated transfer of a HC from the single chondroitin sulfate side
chain of bikunin onto HA (46, 47). This is followed by the
release of bikunin with a single HC (i.e. pre-II) or without HC
(although release of free bikunin has not been observed in
vitro). Bikunin, which harbors the protease-inhibitory activity
of II, is more active in the absence than in the presence of the
HCs on its GAG chain (10). Intriguingly, the tryptase inhibitor
(designated “trypstatin”) present in mast cells has been identi-
fied as bikunin (48, 49). Because only bikunin protein but not
mRNA could be detected in mast cells, the authors concluded
that bikunin was trapped by these cells from serum of circulat-
ing blood (48, 49). It is tempting to speculate that TSG-6 has a
role in liberating bikunin from II and trapping it inside the
mast cell granules or on the surface of granule membranes.
Upon mast cell exocytosis (i.e. the inflammation-induced
release of granule contents into the extracellular space), the
tryptases wouldmeet bikunin and thus be inactivated.Whether
or not TSG-6 plays a regulatory role in these tryptase-bikunin
interactions in mast cell granules remains to be determined.
The role of mast cells in non-IgE-mediated diseases, such as
arthritis, is being increasingly recognized. Mast cells are abun-
dant in inflamed synovial tissues of both humans and mice (50,
51). Mast cell-restricted tryptases can convert matrix metallo-
proteinase-3 (stromelysin) from latent to active form, which
cleaves cartilage aggrecan and also activates synoviocyte pro-
collagenase (52). Mice lacking mast cells (W/Wv mutant) are
less susceptible to inflammatory arthritis than the wild type
counterparts (53). Moreover, mice deficient in both mMCP-6
and mMCP-7 or lacking the enzyme responsible for heparin
biosynthesis are remarkably protected from cartilage degrada-
tion after induction of destructive arthritis (54). In our earlier
studies, intra-articularly injected rmTSG-6 (5) and cartilage-
specific expression of a TSG-6 transgene (7) were both found to
exhibit substantial chondroprotective effects in murinemodels
of arthritis. These observations are consistent with the involve-
ment of TSG-6 in the negative regulation of the activity of
matrix-degrading proteases, probably including mast cell-re-
stricted tryptases.
Mast cell granule components, specificallymMCP-6heparin
complexes, also stimulate neutrophil extravasation via induc-
tion of chemokines (55). Influx of neutrophils into the joints is a
prominent feature of arthritis in both humans and experimen-
tal animals (56, 57). Systemic administration of rmTSG-6 to
mice with PGIA significantly suppressed leukocyte infiltration
into the joints (5). TSG-6 (or its isolated Link module) also
inhibited neutrophil influx into zymosan-stimulated air
pouches, apparently due to reduced amounts of neutrophil-
attracting chemokines at the site of inflammation (58). Con-
versely, the most distinctive phenotype of TSG-6-deficient
mice is the exaggerated recruitment of neutrophils in the joints
after the development of PGIA (21) and in the peritoneal cavity
after peritonitis induction (21). Collectively, these data argue
for a role of TSG-6 in the resolution of inflammation, in part
due to a negative influence on mast cell protease-induced
chemokine production and subsequent leukocyte extravasa-
tion. These novel functions of TSG-6, proposed here in inflam-
matory joint destruction, warrant further investigation.
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